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at increased risk of hepatitis C virus
infection
Handan Wand, Jenny Iversen, David Wilson, Libby Topp, Lisa Maher
ABSTRACT
Objectives: To develop and validate a scoring tool
based on demographic and injecting risk behaviours to
identify those who require additional, non-routine
serological screening for hepatitis C virus (HCV) by
assessing their personal risk.
Design: Cross-sectional and prospective cohorts.
Setting: People who inject drugs (PWID) and attended
Needle and Syringe Programs (NSP) in Australia
during the period from 1998 to 2008.
Participants: Cross-sectional data included 16127
PWID who attended NSP in Australia. Prospective data
included 215 HCV-negative PWID who were recruited
through street-based outreach, methadone clinics in
Australia.
Primary and secondary outcome measures: HCV
seroprevalence in the cross-sectional and HCV
seroconversions in the prospective data sets.
Results: Current study included 16127 PWID who
attended NSP in Australia. Type of drug last injected,
frequency and duration of injecting, sharing needles
and syringes or other injecting equipment and
imprisonment history were associated with HCV
infection in all age groups. Strong relationships
between an individual’s ‘HCV score’ and their risk of
testing HCV antibody positive were observed. An
estimated 78% (95% CI 75% to 81%), 82% (95% CI
80% to 84%), 80% (95% CI 78% to 82%) and 80%
(95% CI 77% to 82%) of HCV infections across the
age groups (<25, 25e29, 30e39 and $40 years)
would be avoided if participants in the upper four
quintiles of HCV scores fell instead into the lowest
quintile.
Conclusions: Knowledge of HCV status has important
implications for public health and care and treatment.
Risk assessment strategies may assist in alerting
PWID who are at increased risk of HCV infection to
present for testing.
INTRODUCTION
Worldwide, infection with hepatitis C virus
(HCV) is common among people who inject
drugs (PWID).
1 Estimates suggest that >70%
of new cases of HCV infection are associated
with injecting drug use.
23Epidemiological
studies have identiﬁed independent risk
factors for HCV infection, including sharing
of contaminated needles and syringes
4e7 and
other injecting equipment,
89female
gender,
61 0duration of injecting
11 and intra-
venous cocaine use.
12 13 Although the risk
factors for incident infection are well estab-
lished, the literature suggests that a number
of barriers may prevent PWID presenting for
screening and many PWID face the possibility
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ARTICLE SUMMARY
Article focus
- Although the risk factors for incident infection
are well established, the literature suggests that
a number of barriers may prevent PWID
presenting for screening.
- Study developed a scoring tool based on
demographic and injecting risk behaviours to
identify those who require additional, non-routine
serological screening for HCV by assessing their
personal risk.
Key messages
- Current clinical practice guidelines recommend
HCV screening of individuals with a history of
injecting drugs.
- However, this recommendation focuses on
a single risk factor (ie, injecting drug use),
whereas considering the cumulative effect of
multiple risk factors among PWID can more
precisely identify people in need of additional
non-routine screening.
Strengths and limitations of this study
- Our prediction equation is based on 11 years of
data and >16000 participants. Ideal risk assess-
ment methods or prediction models should be
derived from large representative samples.
- The study population is limited to those who
participated in the Australian Needle and Syringe
Program Survey, which may result in selection
bias.
- We were not able to differentiate between acute,
recent and chronic infections.
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Open Access Researchof HCV infection with a sense of inevitability, fostered by
structural barriers to risk avoidance.
14 PWID are
a priority population in Australia as HCV prevalence
remains high in this group. The burden of advanced
liver disease (liver failure and hepatocelluar carcinoma)
continues to grow among HCV-infected people.
15 It is
estimated that 5300 Australians are living with HCV-
related cirrhosis, and this ﬁgure is expected to double by
2020 without increased therapeutic intervention.
16
Despite the mounting burden of disease and recent
advances in antiviral treatments, HCV treatment uptake
among PWID remains very low (1%e2% of chronic
hepatitis C cases).
16 A major public health challenge is to
more effectively identify individuals with HCV before the
development of signiﬁcant clinical consequences.
Our study aimed to develop a scoring tool that can be
used by PWID and primary care providers to identify
individuals at increased risk of HCV infection. With
increasing recognition of the clinical beneﬁts of
early diagnosis and treatment uptake,
17e19 a simple
self-administered tool may provide a means for PWID
to identify personal risk and to modify risk behaviour
and/or seek healthcare/further assessment.
A large database of serial cross-sectional samples of
PWID attending Needle and Syringe Programs (NSP) in
Australia (1998e2008) was used to develop a statistical
model underpinning the tool. Cross-sectional (internal)
and prospective (external) validation studies were
carried out on the HCV risk assessment algorithm.
The following characteristics were considered essential
in the development of the new prediction algorithm: (1)
the use of routinely available and minimally intrusive
variables and (2) estimation of the cumulative effect of
concurrent risk factors on the likelihood of HCV prev-
alence. We are unaware of any studies to date that have
quantiﬁed the cumulative effect of concurrent risk
factors on the acquisition of HCV infection among
PWID.
STUDY POPULATION
The Australian Needle and Syringe Program Survey
(ANSPS) is a serial cross-sectional study conducted
annually over a 1e2-week period since 1995. More than
50 NSP sites participate annually, with sites selected on
the basis of geographic coverage, willingness to partici-
pate and an ability to recruit a minimum of 20 survey
respondents. The survey methods have been described
in detail elsewhere.
20e23 In brief, all PWID who attended
participating ANSPS sites during the designated survey
period were invited to participate. Participation was
anonymous and voluntary, and there was no ﬁnancial
reimbursement. Following provision of verbal informed
consent to participate, respondents were asked to
complete a brief self-administered questionnaire on
demographic characteristics and injecting and sexual risk
behaviours (http://www.med.unsw.edu.au/NCHECRweb.
nsf/resources/2011/) and to provide a capillary blood
sample for antibody HIV and HCV testing. The current
study used data for the period 1998e2008, involving
>16000 individuals. Response rates ranged from 38% to
50% during the study period. Previous research has
demonstrated the representativeness of ANSPS samples
of the broader population of NSP clients.
20
Capillary blood was obtained by ﬁnger prick using
single-use disposable lancets and cotton-ﬁbre blotting
paper. Specimens were kept at room temperature at the
survey sites, then couriered to a central collection point
before they were forwarded to the laboratory. A modiﬁed
third generation enzyme immunoassay (Abbott hepatitis
C 3.0; Chicago, Illinois, USA) was used to test for HCV
antibody. A modiﬁed cut-off value for optical density was
calculated to capture >95% of the seronegative popu-
lation. Specimens were considered positive for HCV
antibody if the optical density to cut-off ratio was #1o n
initial and subsequent testing.
Ethical approval was obtained from the Human
Research Ethics Committee (HREC) at the University of
New South Wales as well as from relevant jurisdictional
and site-speciﬁc HRECs.
STATISTICAL ANALYSES
A split-sample method was used to develop and subse-
quently validate a risk equation and scoring system.
Participants were randomly allocated to either the
development (n¼10662; 67%) or internal validation
(n¼5331; 33%) sample data sets.
We selected a range of demographic and injecting
behaviour variables as potential determinants of HCV
infection. These included gender, indigenous status,
imprisonment history, country of birth, language spoken
at home, drug last injected, frequency and duration of
injecting, sharing of needles and syringes and other
injecting equipment (eg, water, ﬁlter, spoon, tourni-
quet), public injecting and drug treatment history. All
analyses were stratiﬁed by age groups (<25, 25e29,
30e39 and $40 years).
We used descriptive statistics to characterise the
groups according to antibody HCV serostatus: mean and
SD for continuous variables and percentages for cate-
gorical variables. Logistic regression was used to create
a predictive model based on the development data set.
We used all non-missing observations available in the
relevant analyses as only a small proportion of observa-
tions had any missing data (except for the variable
‘imprisonment history’). Cox regression analysis was
used to validate the scoring tool for HCV seroconversion
in external validation set. All analyses were conducted
using SAS statistical software V.9.2 (SAS Institute Inc)
and STATA V.10.0.
Derivation of a screening score
Using the development data set (n¼10662), we included
a comprehensive list of predictors known to be associ-
ated with HCVantibody seropositivity in an initial model.
Speciﬁcally, we included the main effects of all variables
listed in table 1 and their interaction effects. We ﬁrst
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pendent variables and HCV seropositivity. Backward
elimination was used to reach the ﬁnal multivariate
model, in which factors with the largest p value were
sequentially deleted until only signiﬁcant predictors
remained. We then created a weighted scoring system by
rounding all regression coefﬁcients up to the nearest
integer (ie, the smallest integer greater than the esti-
mate). This method was based on the b-coefﬁcients (or
log of the ORs) rather than ORs, which can be exces-
sively inﬂuenced by only a few factors.
24e26 Once the
ﬁnal model was deﬁned, we created integer weights for
each variable. We calculated these weights by multiplying
the model coefﬁcients by 10. Using the rounded weights
in the risk function, we estimated the participant-speciﬁc
probabilities of HCV seropositivity and characterised the
degrees of risk based on cut-off points of the probability
distribution.
Cross-sectional internal validation
We examined the predictive validity of the scoring system
using the internal validation data sets (n¼5331). We also
assessed the predictive validity of this scoring system on
the subsequent risk of HCV antibody seroconversion
using prospective data collected from individuals who
visited ANSPS sites multiple times and tested HCV
seronegative at their ﬁrst visit.
We used the cross-sectional data set to check the
sensitivity and robustness of the new screening score. We
computed standard validation measures: the proportion
of antibody HCV seropositive specimens, sensitivity,
speciﬁcity, positive likelihood and negative likelihood
ratio and the area under the receiver operating charac-
teristic curve as discrimination statistics. We also assessed
the diagnostic characteristics of different cut-points
based on the total score in the development as well as
validation data sets. The purpose of this analysis was to
assess whether the combination of risk factors under
consideration could predict those at increased risk with
acceptable accuracy.
Prospective external validation
We have also conducted a prospective external validation
study to assess the performance of the scoring system for
HCV seroconversion among the new PWID. The details
of the study population have been described
Table 1 Risk factors for HCV
Characteristic
HCV seronegative,
N[5214 (49%)
HCV seropositive,
N[5448 (51%)
Mean age at survey (6SD) 29683 4 69
<25 years, % 35 16
25e29 years, % 24 19
30e39 years, % 29 37
$40 years, % 12 28
Female, % 33 35
Indigenous, % 8 10
Mean age at ﬁrst injection (6SD) 20661 9 66
Mean years of injecting (6SD) 9671 5 69
<5 years, % 26 12
5e9 years, % 28 21
10e16 years, % 23 28
$17 years, % 14 40
Ever been in prison, % 17 33
Been in prison last year, % 11 22
Drug injecting behaviours (last month)
Drug injected, %
Amphetamine/methamphetamine 51 28
Heroin 35 48
Cocaine 3 5
Methadone 4 8
Morphine 7 9
Buprenorphine 1 2
Others* 9 8
Injecting daily or more, % 50 58
Receptive sharing needle/syringe, % 15 18
Receptive sharing ancillary equipmentsy, % 33 38
Injected by another, % 14 12
New needle syringe in every injection 72 68
Injected in public 46 52
*Benzos, anabolic steroids, mixed drugs, other drugs or not reported.
yWater, spoon, ﬁlter and tourniquet.
HCV, hepatitis C virus.
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11 In brief, as part of a multisite study between
1999 and 2002, 215 hepatitis C-seronegative PWID were
recruited through street-based outreach, methadone
clinics in South Western Sydney and followed-up at 3e6-
monthly intervals. Using the Cox regression coefﬁcients
in the risk function, the participant-speciﬁc probability
of HIV seroconversion was estimated. A rule to charac-
terise different degrees of risk based on cut-off points of
the probability distribution was then established. We also
assessed the diagnostic features and characterised
different degrees of risk based on cut-off points of the
probability distribution.
Population attributable risk
After we calculated and validated the HCV screening
score, we estimated population attributable risks, which
estimates the percentage of HCV infections that would
not have occurred if all participants had been assigned
the ‘lowest risk’ (ﬁrst quintile) category of the HCV
screening score. We calculated population attributable
risks using a previously described method
27 that was
applied to this study design and appropriate for use with
multivariable adjusted RRs.
RESULTS
Our study population comprised 10662 individuals in
the development data set. Table 1 summarises partici-
pant characteristics by HCV antibody serostatus. The
overall prevalence of HCV was 51%. HCV seropositive
participants tended to be older and more likely to report
a longer duration of injecting, heroin as the drug last
injected, a history of imprisonment, daily or more
frequent injecting, public injecting and sharing needles
and syringes and other injecting equipment.
Table 2 presents the ﬁnal multivariate logistic regres-
sion model derived from the development data set by age
groups. History of imprisonment, duration of injecting
(5e9, 10+ years), drug last injected (heroin, cocaine,
methadone, morphine, buprenorphine and others),
needle and syringe sharing and sharing of ancillary
equipment were all signiﬁcantly associated with increased
risk of antibody HCV seropositivity across all age groups.
Injecting frequency (daily or more) was determined to be
a signiﬁcant risk factor for those aged <30 years. Female
gender was associated with an increased risk of HCV
seroprevalence for those younger than 40 years. Indige-
nous status was a signiﬁcant predictor for HCV infection
among people aged 30e39 years. Drug last injected and
duration of injecting each required multiple categories
to capture the risk gradient, whereas other risk factors
were binary. The risk factors collectively yielded an area
under the receiver operating characteristic curve of 0.73
(95% CI 0.70 to 0.76), 0.72 (95% CI 0.70 to 0.75), 0.73
(95% CI 0.70 to 0.76) and 0.66 (95% CI 0.64 to 0.71) for
the age groups <25, 25e29, 30e39 and $40 years (data
not shown). There were no signiﬁcant interactions
between injecting risk behaviours and gender across age
groups (data not shown).
Table 3 shows the ORs from the logistic regression
models and population attributable risks of HCV infec-
tion for the quintiles of the risk scores by age groups for
the development and validation data sets. There was
a linear trend towards increasing HCV infection with
increasing score regardless of the age groups in both
data sets (trend, p value<0.001). Using the development
data set, we estimated population attributable risks (95%
CI) for the upper four quintiles of the scores. Results
showed that 78% (95% CI 75% to 81%), 82% (95% CI
80% to 84%) and 80% (95% CI 77% to 82%) of HCV
infections across the age groups would be avoided if
participants in the upper four quintiles of the HCV
scores instead fell into the lowest quintile. Results from
the validation data set were consistent with those from
the development data set (table 3). We also assessed the
diagnostic characteristics of cut-points (according to
ﬁrst, second, third and the fourth quintiles in overall
population) for total score in the development as well as
the validation data sets (table 4). An increased risk of
HCV was clearly associated with increasing scores. For
example, a cut-point score of 10 or higher distinguished
a ‘increased risk’ group, with a sensitivity of 96% or
higher; similarly a cut-point of 20 or higher yielded at
least 92% sensitivity in all age groups in the development
data set; in cross-sectional validation, sensitivity was
estimated to be at least 94% across the age groups for
the cut-point of 10/15 or more and at least 76% for 20
or more. Figure 1 illustrates the risk of PWID being
HCV seropositive as a continuous function of the total
score. Across all age groups, increasing scores were
clearly associated with increased risk of HCV antibody
positivity.
A total of 61 HCV seroconversions were observed
during follow-up, with an overall incidence rate of 45.8
per 100 person-years (95% CI 35.6 to 58.8) in our
external prospective validation data set. Results from our
prediction model were consistent with the previous
results and had the acceptable validity (table 5). Higher
number of risk factors associated with increased risk of
HCV seropositivity compared two or less risk factors
(reference) (HR 1.10, 95% CI 0.74 to 1.60, HR 1.15, 95%
CI 0.78 to 1.65, HR 2.17, 95% CI 1.45 to 3.17 and HR
3.19, 95% CI 2.30 to 5.51 for three, four, ﬁve and six or
more risk factors, respectively). Overall sensitivity of the
scoring tool was 73% sensitivity and 33% speciﬁcity
(ﬁgure 2).
DISCUSSION
In this study, we developed a scoring tool based on data
from w16000 PWID who attended ANSPS sites between
1998 and 2008. The tool was validated to more accurately
identify those at increased risk of HCV infection.
Current Australian guidelines recommend HCV anti-
body screening in all individuals with risk factors for
infection regardless of patient characteristics and
settings.
28 Increasing the rate of HCV diagnosis and, in
particular, diagnosis of acute infection and providing
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Hepatitis C infection, injecting drug usersaccess to effective antiviral treatment has the potential to
improve individual quality of life and reduce the burden
of HCV infection. Being unaware of one’s HCV seros-
tatus has been identiﬁed as a major barrier to increasing
HCV treatment uptake, including among PWID.
29 30
While a relatively high proportion (64%) of participants
Table 4 Optimal characteristics of HCV scoring*
Age <25 years Age 25e29 years Age 30e39 years Age ‡40 years
Score
cut-pointsy
Sensitivity
(%)
Speciﬁ-
city (%)
Sensitivity
(%)
Speciﬁ-
city (%)
Sensitivity
(%)
Speciﬁ-
city (%)
Sensitivity
(%)
Speciﬁ-
city (%)
Development data set (n¼10662)
$10 96 17 99 9 99 7 98 10
$15 92 32 95 23 97 15 97 19
$20 74 60 86 42 90 36 94 24
$25 55 74 68 64 73 57 75 54
Validation data set cross-sectional (n¼5465)
$10 96 18 99 8 99 10 99 10
$15 94 32 95 25 97 19 97 15
$20 76 57 88 40 87 43 94 21
$25 59 72 67 61 73 61 74 52
*HCV score : For age <25 years: (female)33 + (indigenous)30 + (injecting 5e9 years)37 + (injecting $10 years)311 + morphine38 + (other
drugs, eg, benzos, anabolic steroids, mixed drugs)37 + (heroin)311 + (cocaine)319 + (methadone)311 + (morphine)38 + (buprenorphine)3
11 + (daily or more)33 + (shared needle and syringe)30 + (shared other equipment)33 + (been in prison)38. For age 25e29 years: (female)3
4 + (indigenous)30 + (injecting 5e9 years)36 + (injecting $10 years)39 + morphine36 + (other drugs, eg, benzos, anabolic steroids, mixed
drugs)35 + (heroin)310 + (cocaine)313 + (methadone)312 + (morphine)35 + (buprenorphine)310 + (daily or more)34 + (shared needle and
syringe)34 + (shared other equipment)30 + (been in prison)36. For age 30e39 years: (female)33 + (indigenous)33 + (injecting 5e9 years)37
+ (injecting $10 years)313 + morphine37 + (other drugs, eg, benzos, anabolic steroids, mixed drugs)36 + (heroin)311 + (cocaine)311 +
(methadone)311 + (morphine)37 + (buprenorphine)310 + (daily or more)30 + (shared needle and syringe)33 + (shared other equipment)3
0 + (been in prison)36. For age $40 years: (female)30 + (indigenous)30 + (injecting 5e9 years)34 + (injecting $10 years)315 + morphine37
+ (other drugs, eg, benzos, anabolic steroids, mixed drugs)34 + (heroin)39 + (cocaine)313 + (methadone)311 + (morphine)37+
(buprenorphine)36 + (daily or more)30 + (shared needle and syringe)33 + (shared other equipment)30 + (been in prison)36.
yApproximate cut-points for the ﬁrst, second, third and the fourth quintiles.
HCV, hepatitis C virus.
Figure 1 Total score versus risk of hepatitis C virus (HCV) infection in cross-validation data set.
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Hepatitis C infection, injecting drug usersin the ANSPS reported recent HCV testing, HCV anti-
body-negative respondents were less likely to do so than
HCV antibody-positive respondents (60% vs 67%). One
in ﬁve (20%) HCV antibody-negative participants had not
been tested for HCV in the last 12 months, and a further
20% had never been tested (http://hiv.cms.med.unsw.
edu.au/ (accessed August 2011)). This suggests that both
uptake and frequency of testing could be improved.
Although our scoring tool was developed for the
prediction of current HCV diagnoses and not incident
HCV in the future, strong consistency in risk factors for
the prediction incident events of HCV was shown in
prospective validation of the tool. Therefore, we expect
that the same set of risk factors in our model plays
an important role in the prediction of future HCV
seroconversion.
The intention of this study was not to identify a unique
and speciﬁc cut-point of risk above which to target
screening, but rather, to assess whether risk factors
under consideration could predict those at increased
risk accurately in order to consider the tool’s use in
facilitating increased screening. With a high background
HCV prevalence of w70% among Australian PWID, all
PWID should be screened for HCV. However, identiﬁ-
cation of just one of our listed risk factors substantially
increased the likelihood of infection. Although Australia
has screening guidelines for hepatitis C, current guide-
lines do not target speciﬁc attributes or injecting risk
behaviours.
28 By focusing on particular characteristics
and speciﬁc high-risk behaviours, tools such as the one
developed in this study may allow for more targeted
identiﬁcation of individuals at increased risk of infec-
tion. If used as a self-administered questionnaire, it is
likely that respondents will answer more accurately.
31
Since the vast majority of new HCV diagnoses in
Australia are among people with a history of injecting
drug use,
20 this tool provides a valuable resource that
could inform the establishment of more focused
national screening guidelines.
Furthermore, although current clinical practice guide-
lines recommend HCV screening of individuals with
a history of injecting drugs, this recommendation focuses
on a single risk factor (ie, injecting drug use), whereas
considering the cumulative effect of multiple risk factors
can more precisely identify people in need of additional
non-routine screening. This is particularly pertinent in
resource-constrained environments (including time-
restricted clinical settings). Our methodology made use
of a range of coexisting risk factors that were identiﬁed by
a rigorous statistical approach in order to accurately
identify the most relevant factors for HCV infection.
Risk calculation approaches have been extensively
used in decision-making about public health and clinical
care and have even been proposed as an alternative to
diagnosis for some diseases.
32 Our risk calculation was
based on a statistical method that yielded a systematic
scoring system for carefully selected predictors, guided
not only by numerical and scientiﬁc evidence but also by
feasibility perspectives. We chose categorised variables
that highlighted the important risk factors to motivate
high-risk persons to be screened or to modify behav-
iours. This combination of factors may explain the
enhanced properties of our scoring tool.
Our study has several strengths, including being the
ﬁrst to validate a predictive model through internal
cross-sectional and prospective data sets. Our prediction
equation is based on 11 years of data and >16000
participants. Ideal risk assessment methods or prediction
models should be derived from large representative
samples. The current study has several limitations. First,
the study population is limited to those who participated
in the ANSPS, which may result in selection bias.
However, the ANSPS has been shown to be broadly
representative of PWID attending NSPs.
20 Second, we
were not able to differentiate between acute, recent and
chronic infections.
Risk factor screening and identiﬁcation allows for
patients to be educated regarding the risks of injection
Table 5 Optimal characteristics of HCV scoring using
external prospective validation (N¼215)
Risk
factors, n
Validation with prospective data set
HR (95% CI) p
<2 Reference
3 1.10 (0.74 to 1.60) 0.667
4 1.15 (0.78 to 1.65) 0.504
5 2.17 (1.45 to 3.17) <0.001
$6 3.19 (2.30 to 5.51) <0.001
Score
cut-points
Validation with prospective data set
Sensitivity (%) Speciﬁcity (%)
$10 89 16
$15 78 33
$20 60 54
$25 41 70
HCV, hepatitis C virus.
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
1-Specificity
Area under ROC curve =0.7291
Figure 2 Sensitivity/speciﬁcity for the prospective validation
data set. ROC, receiver operating characteristic.
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Hepatitis C infection, injecting drug usersdrug use and needle sharing. Appropriate testing and
diagnosis of HCV allows for the patient to be evaluated
for treatment and receive counselling regarding HCV
prevention. In addition to physician education, patient
education campaigns must also be developed to increase
patient compliance with testing recommendations made
by their physicians.
In conclusion, we believe that the screening tool
described here will provide a simple and cost-effective
method of identifying and alerting PWID who are in
need of additional, non-routine HCV screening with
notable predictive validity. A self-assessment method that
helps individual PWID understand their relative
increased risk of infection provides the basis for
increased uptake of screening, diagnosis and antiviral
treatment among this population.
In summary, the tool described here has the potential
to engage current PWID in timely and accurate risk
analysis, potentially modifying risk behaviour, and
increasing uptake of HCV screening and antiviral treat-
ment in this population.
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